Data from EMC - Curated by Toby Galbraith - Last updated 12 September 2017

Licensing authority

EMA (European Medicines Agency)


Synagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:
- Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
- Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
- Children less than 2 years of age and with haemodynamically significant congenital heart disease.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Visit Cystic Fibrosis

Related Content

More information

Category Value
Agency product number EMEA/H/C/000257
Orphan designation No
Date First Approved 13-08-1999
Type Medicinal product subject to medical prescription
Marketing authorisation holder AbbVie Ltd